ClinicalTrials.gg
Active, not recruitingNCT05585320Updated Oct 20, 2026

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of IMM-1-104 Monotherapy (Treatment Group A) and IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) in Advanced Solid Tumor, Pancreatic Adenocarcinoma and Malignant Melanoma (Cutaneous), sponsored by Immuneering Corporation. Active, not recruiting at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Immuneering Corporation · Phase 1/2, Interventional, and Treatment

Updated Oct 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
209
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Melanoma, Cutaneous Malignant with a site in United States — 3 open to participants now, 5 under way, 1 of them phase 3. Melanoma, Cutaneous Malignant · United States.

Started
2022
with 1 other
Phase 1/2
2 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
2 of 10
Immuneering Corporation

Among the 10 studies in Melanoma, Cutaneous Malignant with a site in United States, this one is one of 2 that started in 2022, is one of 2 in phase 1/2, and was the 7th registered.

Melanoma, Cutaneous Malignant

17 studies on the registry are indexed under Melanoma, Cutaneous Malignant; 5 are open to participants now.

Browse Melanoma, Cutaneous Malignant studies →

Open to participants now

3 of the 10 studies in Melanoma, Cutaneous Malignant with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Melanoma, Cutaneous Malignant studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Melanoma, Cutaneous Malignant with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest.

03

Conditions studied

  • Advanced Solid Tumor
  • Pancreatic Adenocarcinoma
  • Malignant Melanoma (Cutaneous)
  • Non-small Cell Lung Cancer (NSCLC)

Keywords

  • pan-RAS
  • KRAS
  • NRAS
  • HRAS
  • Targeted therapy
  • Metastatic cancer
  • Advanced cancer
  • RAS
  • Adenocarcinoma
  • MEK
  • Dual MEK
  • MEK 1/2
  • Mitogen-Activated Protein Kinase (MAPK)
  • G12A
  • G12C
  • G12D
  • G12F
  • G12R
  • G12S
  • G12V
  • G13C
  • G13D
  • G13R
  • Q61H
  • Q61K
  • Q61L
  • Q61R
  • A146T
  • A146V
  • K117N
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be ≥18 years of age
  • Must have or cytologically confirmed diagnosis as follows:

    1. Monotherapy Phase 1: A locally advanced unresectable or solid tumor that harbors a RAS (KRAS, NRAS, or HRAS) activating mutation.
    2. Monotherapy Phase 2a: A locally advanced unresectable or metastatic solid tumor malignancies: pancreatic ductal adenocarcinoma (PDAC), RAS-mutant melanoma, or RAS-mutant non-small cell lung cancer (NSCLC)
    3. Combination therapy (both phases): A locally advanced unresectable or metastatic PDAC
    4. Combination therapy Phase 2a, Treatment D: Second and participants with unresectable stage III or stage IV cutaneous melanoma with BRAF mutation. Must have progressed on or after treatment with an anti-PD-(L)1 monoclonal antibody as the most recent therapy. First day of study treatment must be more than 28 days but less than 12 weeks from the last dose of anti-PD-(L)1 mAb.
    5. Combination therapy Phase 2a, Treatment E: Second and third line participants with unresectable stage III or stage IV cutaneous melanoma. Must have progressed on or after treatment with an anti-PD-(L)1 monoclonal antibody as the most recent therapy. First day of study treatment must be more than 28 days but less than 12 weeks from the last dose of anti-PD-(L)1 mAb.
  • Participants must be treatment naive or received prior systemic standard-of-care treatment as follows:

    1. Monotherapy Phase 1: received at least 1 line of systemic standard-of-care treatment for their advanced or metastatic disease
    2. Monotherapy Phase 2a:

      1. First-line PDAC participants will have received no previous systemic anti-cancer therapy. Second-line PDAC participants will have received no more than one prior systemic anti-cancer therapy.
      2. First-line melanoma participants will have received no previous systemic anti-cancer therapy. Second- and third-line participants will have received and failed one or two prior systemic anti-cancer therapies, respectively.
      3. NSCLC participants will have received at least one and no more than two previous lines of systemic therapy.
    3. Combination therapy (both phases): PDAC participants will have received no previous systemic anti-cancer therapy for their advanced or metastatic disease.
  • Must have evidence of (at least one target lesion) per v1.1 criteria
  • (ECOG) performance status of 0 or 1
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Inability to swallow oral medications
  • Symptomatic, untreated, or actively progressing known central nervous system (CNS)
  • History or concurrent evidence of retinal vein occlusion (RVO) or current risk factors for RVO. History of serous retinopathy, retinal edema, or retinal pigment epithelial detachment (RPED)
  • Impaired cardiovascular function or cardiac disease
  • History of rhabdomyolysis within 3 months prior to start of study treatment
  • Active skin disorder requiring systemic treatment within 3 months prior to the start of study treatment
  • Participants with active, uncontrolled disease or participants actively being treated with tumor necrosis factor-alpha (TNF-alpha) inhibitors for management of their autoimmune disease are excluded
  • Receipt of an allogeneic tissue/solid organ transplant
  • Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
209 participants (actual)

Study arms

  • Experimental
    IMM-1-104 monotherapy (Treatment Group A)

    IMM-1-104 monotherapy for first/second line pancreatic adenocarcinoma; first/second/third line melanoma; or second/third line non small cell lung cancer

    Drug: IMM-1-104 Monotherapy (Treatment Group A)

  • Experimental
    IMM-1-104 in combination with mGnP (Treatment Group B)

    IMM-1-104 in combination with modified gemcitabine and nab-paclitaxel (mGnP) for first line pancreatic adenocarcinoma

    Drug: IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)

  • Experimental
    IMM-1-104 in combination with mFFX (Treatment Group C)

    IMM-1-104 in combination with modified FOLFIRINOX (mFFX) for first line pancreatic adenocarcinoma

    Drug: IMM-1-104 + modified FOLFIRINOX (Treatment Group C)

  • Experimental
    IMM-1-104 in combination with dabrafenib (Treatment Group D)

    IMM-1-104 in combination with dabrafenib for second/third line post-IO melanoma with BRAF mutation

    Drug: IMM-1-104 + dabrafenib (Treatment Group D)

  • Experimental
    IMM-1-104 in combination with pembrolizumab (Treatment Group E)

    IMM-1-104 in combination with pembrolizumab for second/third line post-IO melanoma

    Drug: IMM-1-104 + pembrolizumab (Treatment Group E)

Interventions

  • DrugIMM-1-104 Monotherapy (Treatment Group A)

    Once-daily, oral IMM-1-104 dose administered in 28-day cycles until treatment discontinuation criteria are met

    Also known as: IMM-1-104

  • DrugIMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)

    Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of gemcitabine and nab-paclitaxel until treatment discontinuation criteria are met. Gemcitabine will be administered at a dose of 1000 mg/m\^2 nab-Paclitaxel will be administered at a dose of 125 mg/m\^2

    Also known as: IMM-1-104 + mGnP

  • DrugIMM-1-104 + modified FOLFIRINOX (Treatment Group C)

    Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of modified FOLFIRNOX until treatment discontinuation criteria are met. FOLFIRINOX will be administered as follows: Folinic Acid will be administered at 400 mg/m\^2 Fluorouracil will be administered at 2400 mg/m\^2 Irinotecan will be administered at 150 mg/m\^2 Oxaliplatin will be administered at 85 mg/m\^2

    Also known as: IMM-1-104 + mFFX

  • DrugIMM-1-104 + dabrafenib (Treatment Group D)

    Drug page: Dabrafenib

    Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with twice daily oral dose of dabrafenib until treatment discontinuation criteria are met. Dabrafenib will be administered at a dose of 150mg daily (75mg twice daily).

    Also known as: IMM-1-104 + dabrafenib

  • DrugIMM-1-104 + pembrolizumab (Treatment Group E)

    Drug page: Pembrolizumab

    Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of pembrolizumab in sequence or concurrently depending on the enrolled cohort (two sub cohorts) until treatment discontinuation criteria are met. Pembrolizumab will be administered at a dose of 400mg.

    Also known as: IMM-1-104 + pembro

06

What researchers measure

Primary outcomes

  1. Phase 1: Adverse Events

    Number of participants with adverse events

    Time frame: From treatment initiation through 30 days following the last IMM-1-104 dose

  2. Phase 1: Dose-Limiting Toxicities

    Number of participants with dose-limiting toxicities

    Time frame: The first 21 days of study treatment

  3. Phase 1: Recommended Phase 2 Candidate Optimal Dose

    Selection of candidate optimal dose to take forward into Ph2a

    Time frame: Initiation of study treatment through 21 days (up to approximately 18 months)

  4. Phase 2a: Overall Response Rate

    The proportion of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR), based on RECIST 1.1 criteria

    Time frame: After up to 48 weeks (12 cycles) of study treatment

Secondary outcomes

  1. Phase 1/2a: Maximum Observed Plasma Concentration of IMM-1-104

    Cmax

    Time frame: After 12 weeks (3 Cycles) of study treatment

  2. Phase 1/2a: Time to Reach Maximum Plasma Concentration of IMM-1-104

    Tmax

    Time frame: After 12 weeks (3 Cycles) of study treatment

  3. Phase 1/2a: Area Under Plasma Concentration (AUC) Time Curve of IMM-1-104

    AUC0-t

    Time frame: After 12 weeks (3 Cycles) of study treatment

  4. Phase 2a: Disease Control Rate (DCR)

    The proportion of participants who have a best overall response (BOR) of stable disease (SD) or better

    Time frame: After 16 weeks (4 Cycles) of study treatment

  5. Phase 2a: Progression Free Survival (PFS)

    The time interval between study treatment start and disease progression or death due to any cause.

    Time frame: Up to approximately 2 years

  6. Phase 2a: Duration of Response (DOR)

    The time interval between an assessment of partial response (PR) or better and disease progression or death due to any cause.

    Time frame: Up to approximately 2 years.

  7. Phase 2a: Landmark 3-Month Survival

    The proportion of participants who are still alive after three months on study.

    Time frame: After 3 months of study participation.

  8. Phase 2a: Landmark 6-Month Survival

    The proportion of participants who are still alive after six months on study.

    Time frame: After 6 months of study participation.

  9. Phase 2a: Overall Survival (OS)

    The time interval between study treatment start and death due to any cause.

    Time frame: Up to approximately 2 Years

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2022 (actual). Primary completion is estimated for Jun 2027, 56 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2022
First posted
Oct 18, 2022
StartActual
Oct 31, 2022
Primary completionEst.
Jun 2027was Jun 2026
CompletionEst.
Jun 2028was Jun 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Jun 2027
Oct 20, 2026
Study completion
Jun 2027→Jun 2028
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Primary completion Jun 2026→Jun 2027
    Study completion Jun 2027→Jun 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05585320
Lead sponsor
Immuneering Corporation
Responsible party
Sponsor
First posted
Oct 18, 2022
Start date
Oct 31, 2022
Primary completion
Jun 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Vinny Hayreh, MD
study director · Immuneering Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dabrafenib · Pembrolizumab

Start the discussion